<DOC>
	<DOC>NCT01205269</DOC>
	<brief_summary>The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.</brief_summary>
	<brief_title>The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients with chronic obstructive pulmonary disease (COPD)</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Clinical diagnosis of COPD Current or exsmokers FEV1 40 80% of the predicted normal value (postbronchodilator) and postbronchodilator FEV1/FVC &lt; 70% Any clinically significant disease or disorder Any clinically relevant abnormal findings at screening examinations Family history or presence of glaucoma Need of long term oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>safety</keyword>
	<keyword>inhalation</keyword>
	<keyword>long-acting muscarinic receptor antagonist (LAMA)</keyword>
</DOC>